CGM Device Guide

Medtronic Simplera Sync

The Simplera Sync is not a standalone CGM – it is the sensor component of the MiniMed 780G automated insulin delivery system. If you are on the 780G, the Simplera is your sensor. If you are not on the 780G, it is not available to you.

CGM AID Medtronic

Framework status

5 / 5 All five framework criteria met

✓ T1D included – studied in people with type 1 diabetes

✓ Meal challenge included – rapid glucose rises tested, not just stable periods

✓ Hypoglycaemia challenge included – accuracy tested in the low range

✓ Venous blood reference – the gold standard reference method

✓ Population and indication match – adults and children from age 7 (FDA approval, April 2025)

Data sufficiency: Met – CIP330 pivotal trial, n=243, ages 2-80 years

Device at a glance

Manufacturer	Medtronic Diabetes
Wear duration	6 days + 24-hour grace period (6.5 days total)
±20/20 agreement	Available on the DSNFUK CGM comparison chart. To be confirmed from peer-reviewed publication when available.
Outside ±40/40	Data on the DSNFUK chart. The system-level AID performance (93% time in SmartGuard, CIP330) is the more clinically relevant figure for 780G users.
Calibration required	No fingerstick required. The device is factory calibrated. It does prompt for occasional confirmation checks – these should be performed with a proper finger prick, not by entering the CGM reading.
Design	All-in-one disposable – transmitter and sensor integrated in a single oval pod. No separate transmitter to charge or replace.
Placement	Upper arm only
UK indication	Non-adjunctive – integrated within the MiniMed 780G AID system
Age indication	7 years and older (FDA April 2025). CE mark age range – confirm with Medtronic UK.
AID compatible	MiniMed 780G only. Cannot be used with any other pump or AID system.

[Image: Medtronic Simplera Sync and MiniMed 780G system – awaiting editorial images from Medtronic]

Accuracy

The accuracy figures that matter clinically are the ±20/20 and ±40/40 agreement rates – the proportion of readings accurate enough to support an insulin dosing decision, and the proportion within the outer safety band. Both are available on the DSNFUK CGM comparison chart, which is the reference used in this guide. MARD – a statistical average – tells you little about what matters clinically and is not used here as a primary measure.

The Simplera Sync qualifies for inclusion on the GNL framework with a 5/5 score. For patients in full AID mode on the MiniMed 780G, the SmartGuard algorithm uses its own internal modelling and safety constraints to make insulin delivery decisions – so the system-level performance data from the CIP330 trial (93% of time in SmartGuard mode) provides the more relevant clinical picture than any individual sensor accuracy figure in isolation.

For patients who make any manual dosing decisions from the CGM reading directly, the ±20/20 agreement rate on the DSNFUK chart is the figure to review when comparing the Simplera against other sensors.

The black swan – when to trust and when to check

Between 0.5% and 1% of readings from framework-qualified CGMs fall outside the ±40/40 accuracy band. For Simplera Sync users within the 780G AID system, this means the algorithm may occasionally act on a reading that is significantly wrong. AID systems have safety constraints that limit extreme responses – but no algorithm can fully compensate for a sensor reading that is far outside the true glucose value. See the accuracy page for the precautionary framework and the finger prick habits that remain important even in full AID mode.

A clinical observation from the GNL Podcast (Episode 36, DSN Forum UK): one patient was found to be entering the CGM reading, rather than a finger prick blood glucose, when the Simplera Sync prompted for a confirmation check. This produces a circular confirmation that offers no error correction. If prompted for a check, use a proper finger prick.

The MiniMed 780G ecosystem

The Simplera Sync only makes sense as part of the MiniMed 780G system. The 780G uses SmartGuard technology – a predictive algorithm that adjusts basal insulin delivery and delivers automated correction boluses based on CGM readings and trend data.

SmartGuard AID

The 780G with Simplera Sync targets a glucose level set by the user (typically 100 mg/dL / 5.6 mmol/L or higher) and adjusts basal delivery automatically to maintain that target. It delivers automated correction boluses when glucose is rising above target. CIP330 trial data showed 93% of time spent in SmartGuard mode.

Sensor duration and transitions

The 6.5-day wear period means sensor changes are more frequent than with 10 or 14-day sensors. This is a practical consideration for patients and families – a sensor change roughly every week. Wear is upper arm only.

Calibration prompts

The Simplera Sync is factory calibrated and does not require routine fingerstick calibration. It may prompt for occasional confirmation checks. These should be performed with a proper finger prick blood glucose test from a clean, dry finger – not by entering the CGM reading into the device.

Who this is for

The Simplera Sync is only relevant to patients on the MiniMed 780G system. It is not a standalone CGM choice. If a patient uses the 780G, this is their sensor – the system is designed around it and no other CGM is compatible.

If a patient is choosing between AID systems and the CGM is an important factor in that choice, the Simplera Sync’s 6.5-day wear duration and its accuracy figures on the DSNFUK CGM comparison chart are relevant considerations alongside the 780G’s clinical outcomes data.

Clinical evidence

Medtronic CIP330 pivotal trial. n=243, ages 2-80 years. No serious adverse events. 93% time in SmartGuard mode during AID use. Accuracy data (±20/20 and ±40/40 agreement rates) on the DSNFUK CGM comparison chart. (FDA submission data, April 2025.)
Medtronic FDA approval announcement (April 2025). Simplera Sync approved for ages 7 years and older.
Peer-reviewed publication of pivotal trial data anticipated. Page updated on publication.